Esther Rajavelu
Stock Analyst at UBS
(0.78)
# 4,061
Out of 5,090 analysts
26
Total ratings
50%
Success rate
-17.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $81.68 | -43.68% | 4 | Aug 12, 2025 | |
| APLT Applied Therapeutics | Downgrades: Neutral | $13 → $2 | $0.22 | +823.36% | 3 | Dec 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $19.96 | +60.32% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $458.12 | -53.07% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $36.38 | +100.66% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $9.55 | +1,041.36% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $30.87 | +13.38% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $169.70 | +34.35% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $61.44 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $20.74 | -37.32% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.74 | +474.71% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $81.68
Upside: -43.68%
Applied Therapeutics
Dec 2, 2024
Downgrades: Neutral
Price Target: $13 → $2
Current: $0.22
Upside: +823.36%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $19.96
Upside: +60.32%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $458.12
Upside: -53.07%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $36.38
Upside: +100.66%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $9.55
Upside: +1,041.36%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $30.87
Upside: +13.38%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $169.70
Upside: +34.35%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $61.44
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $20.74
Upside: -37.32%
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $1.74
Upside: +474.71%